Julius Lindblom

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: RHEUMATOLOGY. 2025;64(8):4650-4658
Unsupervised machine learning identifies distinct SLE patient endotypes with differential response to belimumab
Depascale R; Da Mutten R; Lindblom J; Cetrez N; Palazzo L; Iaccarino L; Doria A; Nikolopoulos D; Gatto M; Parodis I
Article: ANNALS OF THE RHEUMATIC DISEASES. 2025;84(7):1164-1179
Novel IgG and IgA autoantibodies validated in two independent cohorts are associated with disease activity and determine organ manifestations in systemic lupus erythematosus: implications for anti-LIN28A, anti-HMGN5, anti-IRF5, and anti-TGIF1
Lindblom J; Lagutkin D; Sherina N; Idborg H; Beretta L; Borghi MO; Peyper JM; Barturen G; Jakobsson P-J; Alarcon-Riquelme ME; Nikolopoulos D; Parodis I
Article: ANNALS OF THE RHEUMATIC DISEASES. 2025;84(7):1180-1194
New IgG and IgA autoantibody specificities against DNA-binding and RNA-binding proteins discriminate systemic lupus erythematosus from health and non-lupus autoimmunity-could anti-LIN28A enhance precision in diagnostics?
Parodis I; Lagutkin D; Lindblom J; Idborg H; Beretta L; Borghi MO; Peyper JM; Barturen G; Jakobsson P-J; Alarcon-Riquelme ME; Sherina N; Nikolopoulos D
Article: RHEUMATOLOGY. 2025;64(7):4257-4266
Belimumab efficacy in mucocutaneous manifestations of systemic lupus erythematosus: a large post hoc analysis of five phase III clinical trials
Grosso G; Giannopoulou N; Tsoi A; Cetrez N; Nikolopoulos D; Lindblom J; Parodis I
Article: RHEUMATOLOGY. 2025;64(6):3598-3605
Treat-to-target in SLE: is serology important? Results from an integrated analysis of five randomized clinical trials of belimumab
Gomez A; Lindblom J; Parodis I; Bertsias G
Article: RHEUMATOLOGY. 2025;64(5):2697-2705
Trajectories of disease evolution upon treatment initiation in systemic lupus erythematosus: results from four clinical trials of belimumab
Parodis I; Lindblom J; Tsoi A; Palazzo L; Sporre KB; Enman Y; Nikolopoulos D; Beretta L
Article: RMD OPEN. 2025;11(2):e005444
Outcomes of patients with systemic lupus erythematosus treated with belimumab: a post hoc efficacy analysis of five phase III clinical trials by British Isles Lupus Assessment Group-based Combined Lupus Assessment criteria
Parodis I; Lindblom J; Palazzo L; Cetrez N; Oon S; Ala H; van Vollenhoven RF; Morand E; Levitsky A; Nikpour M
Article: RHEUMATOLOGY ADVANCES IN PRACTICE. 2025;9(2):rkaf032
Predicting EQ-5D full health state in systemic lupus erythematosus using machine learning algorithms
Botto J; Cetrez N; Nikolopoulos D; Regardt M; Heintz E; Lindblom J; Parodis I
Article: RHEUMATOLOGY INTERNATIONAL. 2024;44(12):2853-2861
COVID-19 vaccination-related delayed adverse events among people with rheumatoid arthritis: results from the international COVAD survey
Dey M; Doskaliuk B; Parodis I; Lindblom J; Wincup C; Joshi M; Dey D; Katchamart W; Kadam E; Sen P; Shinjo SK; Nune A; Goo PA; Ziade N; Chen YM; Traboco LS; Gutierrez CET; Vaidya B; Agarwal V; Gupta L; Nikiphorou E
Article: LANCET RHEUMATOLOGY. 2024;6(11):e751-e761
Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trials
Parodis I; Lindblom J; Levy RA; Zen M; Cetrez N; Gomez A; Oon S; Henning C; Khamashta M; Quasny HA; Chauhan D; Askanase A; van Vollenhoven R; Nikpour M
Article: RHEUMATOLOGY. 2024;63(9):2494-2502
Patients with NPSLE experience poorer HRQoL and more fatigue than SLE patients with no neuropsychiatric involvement, irrespective of neuropsychiatric activity
Nikolopoulos D; Cetrez N; Lindblom J; Palazzo L; Enman Y; Parodis I
Article: RHEUMATOLOGY INTERNATIONAL. 2024;44(9):1679-1689
Neuropsychiatric involvement in systemic lupus erythematosus contributes to organ damage beyond the nervous system: a post-hoc analysis of 5 phase III randomized clinical trials
Nikolopoulos D; Cetrez N; Lindblom J; Parodis I
Article: RHEUMATOLOGY INTERNATIONAL. 2024;44(10):1923-1933
Breakthrough SARS-CoV-2 infection in fully vaccinated patients with systemic lupus erythematosus: results from the COVID-19 Vaccination in Autoimmune Disease (COVAD) study
Palazzo L; Lindblom J; Olsson EK; Nikiphorou E; Wincup C; Saha S; Shaharir SS; Katchamart W; Goo PA; Traboco L; Chen Y-M; Lilleker JB; Nune A; Pauling JD; Agarwal V; Dzifa D; Gutierrez CET; Caballero-Uribe CV; Chinoy H; Agarwak V; Gupta L; Parodis I
Article: ANNALS OF THE RHEUMATIC DISEASES. 2024;83(7):889-900
Molecular characterisation of lupus low disease activity state (LLDAS) and DORIS remission by whole-blood transcriptome-based pathways in a pan-European systemic lupus erythematosus cohort
Parodis I; Lindblom J; Barturen G; Ortega-Castro R; Cervera R; Pers J-O; Genre F; Hiepe F; Gerosa M; Kovacs L; De Langhe E; Piantoni S; Stummvoll G; Vasconcelos C; Vigone B; Witte T; Alarcon-Riquelme ME; Beretta L
Article: KIDNEY INTERNATIONAL REPORTS. 2024;9(6):1817-1835
Interferon and B-cell Signatures Inform Precision Medicine in Lupus Nephritis
Parodis I; Lindblom J; Toro-Dominguez D; Beretta L; Borghi MO; Castillo J; Carnero-Montoro E; Enman Y; Mohan C; Alarcon-Riquelme ME; Barturen G; Nikolopoulos D; PRECISESADS Clinical Consortium OBOPREC
Article: RHEUMATOLOGY. 2024;63(3):798-808
Determinants of neuropsychiatric flares in patients with systemic lupus erythematosus: results from five phase III trials of belimumab
Palazzo L; Lindblom J; Cetrez N; Ala H; Parodis I
Article: JOURNAL OF CLINICAL MEDICINE. 2023;12(24):7542
COVID-19 Vaccination-Related Delayed Adverse Events among Patients with Systemic Lupus Erythematosus
Dey M; Doskaliuk B; Lindblom J; Nikiphorou E; Wincup C; Fathima M; Saha S; Shaharir SS; Katchamart W; Goo PA; Traboco L; Chen Y-M; Kadam E; Lilleker JB; Nune A; Pauling JD; Agarwal V; Dey D; Toro Gutierrez CE; Caballero CV; Chinoy H; Aggarwal R; Agarwal V; Gupta L; Parodis I
Article: RHEUMATOLOGY. 2023;62(12):3916-3923
Sensitivity analysis of EQ-5D-3L index scores in terms of discriminative and known-groups validity in SLE: introducing Adequate Health State
Hua N; Gomez A; Lindblom J; Emamikia S; Enman Y; Grannas D; Heintz E; Regardt M; Parodis I
Article: FRONTIERS IN IMMUNOLOGY. 2023;14:1257085
Serum profiling identifies CCL8, CXCL13, and IL-1RA as markers of active disease in patients with systemic lupus erythematosus
Lindblom J; Beretta L; Borghi MO; Alarcon-Riquelme ME; Parodis I
Article: CLINICAL IMMUNOLOGY. 2023;254:109713
Molecular architecture of proliferative lupus nephritis as elucidated using 50-plex imaging mass cytometry proteomics
Titus ASCLS; Tan Y; Tran P; Lindblom J; Ivbievbiokun M; Xu Y; Zheng J; Parodis I; Cai Q; Chang A; Chen S-H; Zhao M; Mohan C
Visa fler

Alla övriga publikationer

Doctoral thesis: 2025
Precision medicine and patient perspectives in systemic lupus erythematosus
Lindblom J
Letter: KIDNEY INTERNATIONAL REPORTS. 2024;9(10):3077-3078
Response to Comment on "Effect of Belimumab on Preventing De Novo Renal Lupus Flares"
Parodis I; Gomez A; Lindblom J; Rovin BH
Corrigendum: JOURNAL OF AUTOIMMUNITY. 2023;140:103052
Distinct gene dysregulation patterns herald precision medicine potentiality in systemic lupus erythematosus (vol 136, 103025, 2023)
Lindblom J; Toro-Dominguez D; Carnero-Montoro E; Beretta L; Borghi MO; Castillo J; Enman Y; Mohan C; Alarcon-Riquelme ME; Barturen G; Parodis I
Review: JOURNAL OF CLINICAL MEDICINE. 2022;11(19):5759
Current Insights on Biomarkers in Lupus Nephritis: A Systematic Review of the Literature
Palazzo L; Lindblom J; Mohan C; Parodis I
Review: CURRENT OPINION IN RHEUMATOLOGY. 2022;34(2):139-149
Diagnostic, predictive and prognostic biomarkers in systemic lupus erythematosus: current insights
Lindblom J; Mohan C; Parodis I

Anställningar

Anknuten till Forskning, Medicin, Solna, Karolinska Institutet, 2024-2027
Doktorand, Medicin, Solna, Karolinska Institutet, 2022-2024

Examina och utbildning

Medicine Doktorsexamen, Institutionen för medicin, Solna, Karolinska Institutet, 2025
Läkarexamen, Karolinska Institutet, 2021

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI